Thyroid cancer

Thyroid Cancer

  • Somatic Mutation: Solid Tissue Molecular Profiling in Thyroid Cancer

    Somatic Mutation Brochure arrow icon   Somatic Mutation Request Form arrow icon

    1. Thyroid Cancer Test Panel (DNA)

    In anaplastic thyroid cancer (ATC), BRAF p.V600E mutation occurs in ~40% of patients with papillary thyroid carcinoma (PTC) and is associated with a more aggressive disease.1,2

    Genes sequenced in this panel include:

    Scroll indicator
    BRAFKRASNRASRET
    Scroll indicator

    2. Medullary Thyroid Cancer (MTC) Panel

    Medullary thyroid cancer (MTC) is associated with oncogenic mutations in RET (40-60%) that can be targeted by therapeutic treatments.3

    Genes sequenced in this panel include:

    • Oncogenic mutations in RET

    How to Order Somatic Mutation Thyroid Cancer Gene Panel

    When to Order:

    • At diagnosis or on therapy for treatment selection.

    Request Form Instructions:

    • Fill out our Somatic Mutation testing request form.

    Specimen Details:

    • Fresh formalin-fixed paraffin-embedded (FFPE) of 5-10 μm thickness from the tumour tissue.

    Test Cost:

    • Thyroid Cancer Test Panel (DNA): No Medicare rebate available. An out-of-pocket fee of $400 applies.

    • Medullary Thyroid Cancer (MTC) Panel: No Medicare rebate available. An out-of-pocket fee of $400.

    Turnaround Time:

    • 5-7 business days from the sample receipt date.


    References
    1. Cohen Y et al., (2004) Clin Cancer Res 10(8):2761–2765.
    2. Xing M et al., (2005) J Clin Endocrinol Metab 90(12):6373–6379.
    3. Malone E et al., Genome Medicine (2020). Molecular profiling for precision cancer therapies 12:8.

About the Author

Associate Professor Mirette Saad

Associate Professor Mirette Saad

MBBS(Hons) MD(Hons) MAACB FRCPA PhD

Associate Professor Mirette Saad

MBBS(Hons) MD(Hons) MAACB FRCPA PhD
Location: Clayton (VIC)
Speciality: Chemical Pathology
Areas of Interest:
  • antenatal screening
  • cancer genetics
  • clinical research and medical teaching
  • endocrine
  • fertility testing
  • molecular genetics
  • nipt
  • precision medicine
  • pharmacogenetics
About

Associate Professor Mirette Saad is a Consultant Chemical Pathologist and National Director of Molecular Genetics at Australian Clinical Labs. She holds a Fellowship with honours in Chemical and Molecular Pathology, with a subspeciality in Microbiology, obtained overseas. A/Prof Saad received her NHMRC-sponsored PhD in Cancer Genetics from the University of Melbourne and the Peter MacCallum Cancer Institute. Alongside her teaching and research roles, A/Prof Saad is a registered medical practitioner with AHPRA, a Chemical Pathology Fellow of the Royal College of Pathologists of Australasia (FRCPA), and a Member of the Australasian Association of Clinical Biochemistry and Laboratory Medicine (AACB) by examination. She is Chair of the RCPA Chemical Pathology Advisory Committee and Chair of Precision Medicine Services at Australian Clinical Labs. At Clinical Labs, A/Prof Saad leads Molecular Genetics testing for NIPT, antenatal screening, fertility, personalised drug therapy and cancer.